Mitochondrial biology and the identification of biomarkers of Huntington's disease

被引:6
|
作者
Neueder, Andreas [1 ]
Orth, Michael [1 ,2 ]
机构
[1] Ulm Univ, Dept Neurol, Ulm, Germany
[2] Neurozentrum Siloah, SwissHuntingtons Dis Ctr, Worbstr 312, CH-3073 Gumligenbei Bern, Switzerland
关键词
fission and fusion; huntingtin fragment; mitochondrial quality control; mtDNA; splicing; TRANSCRIPTION FACTOR-A; ISOLATED BRAIN MITOCHONDRIA; CYTOCHROME-C RELEASE; YAC128 MOUSE MODEL; COMPLEX-II DEFECTS; DNA COPY NUMBER; MUTANT HUNTINGTIN; STRIATAL NEURONS; CAG REPEAT; NUCLEAR-LOCALIZATION;
D O I
10.2217/nmt-2019-0033
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Apart from finding novel compounds for treating Huntington's disease (HD) an important challenge at present consists in finding reliable read-outs or biomarkers that reflect key biological processes involved in HD pathogenesis. The core elements of HD biology, for example, HTT RNA levels or protein species can serve as biomarker, as could measures from biological systems or pathways in which Huntingtin plays an important role. Here we review the evidence for the involvement of mitochondrial biology in HD. The most consistent findings pertain to mitochondrial quality control, for example, fission/fusion. However, a convincing mitochondrial signature with biomarker potential is yet to emerge. This requires more research including in peripheral sources of human material, such as blood, or skeletal muscle.
引用
收藏
页码:243 / 255
页数:13
相关论文
共 50 条
  • [1] A comprehensive perspective of Huntington?s disease and mitochondrial dysfunction
    Dai, Yinghong
    Wang, Haonan
    Lian, Aojie
    Li, Jinchen
    Zhao, Guihu
    Hu, Shenghui
    Li, Bin
    MITOCHONDRION, 2023, 70 : 8 - 19
  • [2] Challenges of Huntington's disease and quest for therapeutic biomarkers
    Kotrcova, Eva
    Jarkovska, Karla
    Valekova, Ivona
    Zizkova, Martina
    Motlik, Jan
    Gadher, Suresh Jivan
    Kovarova, Hana
    PROTEOMICS CLINICAL APPLICATIONS, 2015, 9 (1-2) : 147 - 158
  • [3] Mitochondrial dynamics and quality control in Huntington's disease
    Guedes-Dias, Pedro
    Pinho, Brigida R.
    Soares, Tania R.
    de Proenca, Joao
    Duchen, Michael R.
    Oliveira, Jorge M. A.
    NEUROBIOLOGY OF DISEASE, 2016, 90 : 51 - 57
  • [4] PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease
    Chiang, Ming-Chang
    Chern, Yijuang
    Huang, Rong-Nan
    NEUROBIOLOGY OF DISEASE, 2012, 45 (01) : 322 - 328
  • [5] Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease
    Quintanilla, Rodrigo A.
    Johnson, Gail V. W.
    BRAIN RESEARCH BULLETIN, 2009, 80 (4-5) : 242 - 247
  • [6] Mitochondrial structural and functional dynamics in Huntington's disease
    Reddy, P. Hemachandra
    Mao, Peizhong
    Manczak, Maria
    BRAIN RESEARCH REVIEWS, 2009, 61 (01) : 33 - 48
  • [7] Mitochondrial Dysfunction in Huntington's Disease
    Carmo, Catarina
    Naia, Luana
    Lopes, Carla
    Cristina Rego, A.
    POLYGLUTAMINE DISORDERS, 2018, 1049 : 59 - 83
  • [8] The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease
    Polyzos, Aris A.
    McMurray, Cynthia T.
    MECHANISMS OF AGEING AND DEVELOPMENT, 2017, 161 : 181 - 197
  • [9] Fluid and imaging biomarkers for Huntington's disease
    Zeun, Paul
    Scahill, Rachael I.
    Tabrizi, Sarah J.
    Wild, Edward J.
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2019, 97 : 67 - 80
  • [10] Involvement of CRMP2 in Regulation of Mitochondrial Morphology and Motility in Huntington's Disease
    Brustovetsky, Tatiana
    Khanna, Rajesh
    Brustovetsky, Nickolay
    CELLS, 2021, 10 (11)